Compare RAVE & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | TCRX |
|---|---|---|
| Founded | 1958 | 2018 |
| Country | United States | United States |
| Employees | 24 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 49.4M |
| IPO Year | 1995 | 2021 |
| Metric | RAVE | TCRX |
|---|---|---|
| Price | $2.80 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 25.6K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.76 | ★ 12.28 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $15,120,000.00 | $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | $19.40 | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $2.25 | $0.29 |
| 52 Week High | $3.75 | $2.57 |
| Indicator | RAVE | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 21.50 |
| Support Level | $2.71 | N/A |
| Resistance Level | $3.43 | $0.82 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 11.43 | 5.46 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.